Prophylactic Pregabalin to Decrease Pain During Medication Abortion
Authors:
- EmmaKate B. FriedlanderEFEmmaKate B. Friedlander
- Reni SoonRSReni Soon
- Jennifer SalcedoJSJennifer Salcedo
- James DavisJDJames Davis
- Mary TschannMTMary Tschann
- Bliss KaneshiroBKBliss Kaneshiro
- 1 September 2018
- journal article
- conference paper
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 132 (3) , 612-618
Abstract
OBJECTIVE: To evaluate whether prophylactic pregabalin reduces pain experienced with medication abortion. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of women initiating medication abortion with mifepristone and buccal misoprostol up to 70 days of gestation. Participants were randomized to 300 mg oral pregabalin or a placebo immediately before misoprostol. The primary outcome was maximum pain on an 11-point numerical rating scale, reported using real-time electronic surveys over 72 hours. Secondary outcomes included pain at each time point, ibuprofen and narcotic use, side effects, and satisfaction. We estimated that 110 women would be required to have 80% power to detect a difference in pain of 1.3 points. RESULTS: Between June 2015 and October 2016, 241 women were screened and 110 were randomized (56 pregabalin, 54 placebo). Three were lost to follow-up. The primary outcome of mean maximum pain in the pregabalin group was 5.0±2.6 vs 5.5±2.2 in the placebo group (P=.32). Excluding medication taken before the study capsule, ibuprofen was used by 64% (35/55) of the pregabalin group vs 87% (45/52) placebo (P<.01). Narcotics were used by 29% (16/55) of the pregabalin group vs 50% (26/52) placebo (P<.03). More dizziness (P<.001), sleepiness (P<.04), and blurred vision (P<.05) occurred in the pregabalin group. Satisfaction scores for the analgesic regimen were higher in the pregabalin group (very satisfied: 47% vs 22%; P=.006). CONCLUSION: Compared with placebo, 300 mg pregabalin coadministered with misoprostol during medication abortion did not significantly decrease maximum pain scores. Women who received pregabalin were less likely to require any ibuprofen or narcotic and were more likely to report higher satisfaction with analgesia, despite an increase in dizziness, sleepiness, and blurred vision. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02782169.Keywords
This publication has 13 references indexed in Scilit:
- Perioperative Pregabalin for Acute Pain After Gynecological Surgery: A Meta-analysisClinical Therapeutics, 2015
- Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysisBritish Journal of Anaesthesia, 2014
- Pain during medical abortion, the impact of the regimen: A neglected issue? A reviewThe European Journal of Contraception & Reproductive Health Care, 2014
- Determination of the Effective Dose of Pregabalin on Human Experimental Pain Using the Sequential Up-Down MethodThe Journal of Pain, 2014
- Pregabalin: latest safety evidence and clinical implications for the management of neuropathic painTherapeutic Advances in Drug Safety, 2013
- Prophylactic Compared With Therapeutic Ibuprofen Analgesia in First-Trimester Medical AbortionObstetrics & Gynecology, 2013
- Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled studyFertility and Sterility, 2009
- Treatment of pain during medical abortionContraception, 2006
- A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestationBJOG: An International Journal of Obstetrics & Gynaecology, 2005
- A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestationContraception, 2003